Compare SY & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SY | VYGR |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 272.8M | 227.2M |
| IPO Year | 2018 | 2015 |
| Metric | SY | VYGR |
|---|---|---|
| Price | $2.80 | $3.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $5.50 | ★ $16.50 |
| AVG Volume (30 Days) | 367.1K | ★ 438.7K |
| Earning Date | 05-15-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.91% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,135,000.00 |
| Revenue This Year | $38.64 | $34.04 |
| Revenue Next Year | $30.63 | $7.92 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.82 | $2.65 |
| 52 Week High | $6.28 | $5.55 |
| Indicator | SY | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 44.34 | 37.66 |
| Support Level | $2.80 | $3.27 |
| Resistance Level | $2.93 | $4.38 |
| Average True Range (ATR) | 0.16 | 0.25 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 14.05 | 1.60 |
So-Young International Inc is an online destination for discovering, evaluating, and reserving medical aesthetic services in China. Its business model comprises four integrated components: professional content and its distribution through social media networks and its targeted media platforms in China, a social community characterized by signature user-generated content, Online reservation services for a medical aesthetic treatment, and the research, development, production, sales and agency of laser and other optoelectronic medical beauty equipment. It generates revenue from information services fees and reservation services fees from medical aesthetic service providers.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.